CervoMed rises as experimental drug shows benefit in early-stage dementia patients

Shares of biotech firm CervoMed CRVO.O rise 8% to $4.58

Co says new trial analysis shows its experimental drug neflamapimod worked best in people with early-stage dementia with Lewy bodies, a brain condition that affects memory, thinking and movement

Says the disease worsened slower in patients with low pTau181 treated with neflamapimod, versus placebo; pTau181 is a blood marker linked to Alzheimer’s-related brain changes

Neflamapimod is designed to reduce brain inflammation and nerve cell problems; higher drug levels in blood were linked to better clinical outcomes - CRVO

Co plans to start a larger late-stage trial in the second half of 2026; says neflamapimod has been generally well tolerated across studies

CRVO rose about three-fold in 2025